Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Vishala T. Neppalli"'
Autor:
Siegfried Janz, Brian Van Ness, Joseph B. Bolen, Mark Manfredi, Erik Kupperman, Allison J. Berger, Vishala T. Neppalli, Mary Carsillo, Paul Hales, Ping Li, Olga Tayber, Zhi Li, Michael Pickard, Ray Liu, Matthew D. Silva, Ozlem Subakan, Daniel P. Bradley, Jennifer Terkelsen, Kristen Bano, Jill Donelan, Bret Bannerman, Michael Fitzgerald, Edmund C. Lee
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bf51cd992431bfa10c2e6773dbd8053
https://doi.org/10.1158/1078-0432.c.6520107
https://doi.org/10.1158/1078-0432.c.6520107
Autor:
Siegfried Janz, Brian Van Ness, Joseph B. Bolen, Mark Manfredi, Erik Kupperman, Allison J. Berger, Vishala T. Neppalli, Mary Carsillo, Paul Hales, Ping Li, Olga Tayber, Zhi Li, Michael Pickard, Ray Liu, Matthew D. Silva, Ozlem Subakan, Daniel P. Bradley, Jennifer Terkelsen, Kristen Bano, Jill Donelan, Bret Bannerman, Michael Fitzgerald, Edmund C. Lee
PDF file - 108K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24fd400a1ca08e8405e5d218dd1e0d4b
https://doi.org/10.1158/1078-0432.22444227.v1
https://doi.org/10.1158/1078-0432.22444227.v1
Autor:
Cory Mavis, Natalie M Czuczman, Juan Gu, Song Liu, Francisco J. Hernandez-Ilizaliturri, Pavel Klener, Myron S. Czuczman, Qiang Hu, Sarah Frys, Petra Vockova, Matthew J. Barth, Vishala T. Neppalli
Publikováno v:
Blood. 127:1128-1137
Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and inevitable development of refractory disease, stressing the need to develop alternative therapeutic strategies. To this end, we evaluated pevonedistat (MLN4924), a novel
Autor:
Angela Kader, Vishala T. Neppalli, Sheila N.J. Sait, Joseph D. Tario, Paul K. Wallace, Jenna Nichols, Suchitra Sundaram, Alan D. Hutson, Nishitha Reddy, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Cory Mavis, Adrienne Groman, AnneMarie W. Block, Bora E. Baysal
Publikováno v:
Blood. 134:2817-2817
Background: Minimal residual disease (MRD) status is an independent prognostic marker for response duration in patients with mantle cell lymphoma (MCL). Rituximab-based therapy led to a molecular remission (MR) in 48% young MCL patients treated with
Publikováno v:
Journal of the American Academy of Dermatology. 65:739-748
Background Primary cutaneous CD4 + small/medium-sized pleomorphic T-cell lymphoma (PCSM-TCL) was defined as a provisional entity in the 2005 World Health Organization—European Organization for Research and Treatment of Cancer classification of cuta
Autor:
Olga Tayber, Erik Kupperman, Zhi Li, Joseph B. Bolen, Ping Li, Kristen Bano, Jennifer Terkelsen, Allison Berger, Brian G Van Ness, Michael D. Pickard, Matthew D. Silva, Mary Carsillo, Paul Hales, Michael Fitzgerald, Siegfried Janz, Ozlem Subakan, Daniel P. Bradley, Mark Manfredi, Edmund Lee, Vishala T. Neppalli, Bret Bannerman, Jill Donelan, Raymond W. Liu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23)
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bort
Autor:
Elizabeth Kelley, Annette J. Schlueter, Vishala T. Neppalli, Christie P. Thomas, Aash P. Bhatt
Publikováno v:
American journal of kidney diseases : the official journal of the National Kidney Foundation. 57(4)
Osmotic nephrosis with acute kidney injury can follow the administration of colloid volume expanders and other hypertonic solutions. In the kidney transplant setting, such agents may be used in the donor before organ procurement and in the recipient
Autor:
Dong-Mi Shin, Hartmut Goldschmidt, Vishala T. Neppalli, Herbert C. Morse, Siegfried Janz, Wendy Dubois, Sebastian Rutsch
Publikováno v:
Blood. 115(9)
Interleukin-6 (IL-6) plays a critical role in the natural history of human plasma cell neoplasms (PCNs), such as plasma cell myeloma and plasmacytoma (PCT). IL-6 is also at the center of neoplastic plasma cell transformation in BALB/c (C) mice carryi
Autor:
Shipra Gandhi, Vishala T. Neppalli, George Deeb, Myron S. Czuczman, Francisco J Hernandez-Ilizaliturri
Publikováno v:
Blood. 122:5064-5064
Background DLBCL is the most common type of non-Hodgkin lymphoma, which demonstrates morphologic, immunophenotypic, molecular, and clinical heterogeneity. Gene expression profiling studies define two molecular subtypes of DLBCL, namely germinal cente